domingo, 15 de noviembre de 2026
BuscarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each, so you can check any claim. How we source
Source document· March 27, 2026

Barclays (LSE:BARC) Valuation Check After Recent Share Price Weakness And Mixed Return Profile

View original at finance.yahoo.com
Barclays (LSE:BARC) Valuation Check After Recent Share Price Weakness And Mixed Return Profile Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge…
Opening lines of the source · short snapshot: read the full document at the original

Lo que extrajimos de esta fuente

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Tougher competition for UK deposits, or setbacks integrating acquisitions like Tesco Bank or a potential Evelyn Partners deal, could quickly challenge the upbeat valuation view

    60% confidence
  • The most followed view sees Barclays as 27.2% undervalued with a fair value of £5.30 versus current price of £3.8545

    60% confidence
  • Predictable, multi-year structural hedge income and net interest income momentum, supported by disciplined deposit management, asset repricing and loan growth, will underpin consistent NII growth and support progressive shareholder distributions, enhancing earnings visibility

    60% confidence
  • Barclays is trading at an intrinsic discount of about 58% with a value score of 6

    60% confidence

Data points we hold from this source

Barclays · one year total shareholder return30 percent
Barclays · thirty day return-16 percent
Barclays · three month return-18 percent
Barclays · value score6 score
Barclays · year to date return-20 percent
Barclays · fair value5.30 GBP
Barclays · five year total shareholder return150 percent
Barclays · intrinsic discount58 percent
Barclays · one month return-16 percent
Lo que sabemos · la inteligencia detrás de esta página
En vivo desde el sustrato
Lo que estamos viendo
Q4 2026 Biotech Catalyst Cluster: Late-Stage Data and PDUFA Dates Converge
Early-to-mid November 2026 is a dense run of clinical readouts and Q3 earnings at AHA, AASLD, ACR and ASH. Mid-cap biotechs (Vir, Mineralys, Arrowhead, Oryzon, Novartis, J&J) are reporting data that feeds into regulatory decisions. The next ones are the ivonescimab BLA (Nov 14) and the lorundrostat PDUFA (Dec 22), followed by ECLIPSE 2/3 and Maritime-1 readouts in Q1 2027. The list also includes an unrelated delisting track (EGM Nov 19, application Jan 25, 2027), and the facts have no AI or fintech content.
Nuestra lectura de los datos ›
Señales que seguimos
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patrones que observamos ›
Donde las fuentes discrepan
Fuentes reconciliadas, sin conflictos abiertos ahora mismo.
Señalamos los conflictos abiertamente ›
Verificado recientemente
✓ Verificado con la fuente original
4,959
hechos rastreados a su fuente, y señalamos los que no se sostienen.
101 entidades seguidas4,959 hechos verificados con la fuente5,585 documentos fuente archivados
Consulta estos datos → isubstrate.com
Barclays (LSE:BARC) Valuation Check After Recent Share Price Weakness And Mixed Return Profile: Source | Via News | es.via.news